Article
Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy.
The American journal of tropical medicine and hygiene - 1 Aug 2005
Slater Madeline, Kiggundu Moses, Dokomajilar Chris, Kamya Moses R, Bakyaita Nathan, Talisuna Ambrose, Rosenthal Philip J, Dorsey Grant
Abstract excerpt
The use of molecular genotyping to distinguish recrudescence from new infections has become common in antimalarial clinical trials. However, methods used to interpret genotyping results have not been standardized. We analyzed data from 3,000 patients enrolled in clinical trials at seven sites in Uganda. Late treatment failure requiring genotyping occurred in 51% of the patients. Among samples successfully...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.